Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 4 Japan Drug Majors See Half-Year Profit Fall on One-Off Factors, but Global Flagships Thrive
November 7, 2017
- Pfizer Adjusts Shipments of Selara, Others Due to Damage Caused by Hurricane
November 7, 2017
- JCR Side Asked GSK to Revise Capital Alliance: CEO Ashida
November 6, 2017
- Mitsubishi Tanabe to Acquire Stelic, Adding Nucleic Acid Drugs to Lineup to Accelerate Business Development in US
November 6, 2017
- Shionogi, UMN Pharma Conclude Capital Alliance; Tie Up in Infectious Disease Field
November 2, 2017
- Kirin, Amgen Wind Up Drug Development Joint Venture
November 2, 2017
- EA Pharma Licenses Secondary Hyperparathyroidism Med AJT240 to JW Pharma
November 2, 2017
- Mitsubishi Tanabe’s HIF-PH Inhibitor Enters Japan PIII
November 2, 2017
- Eisai CEO Sees 4 Global Brands as Drivers through FY2020
November 2, 2017
- Eisai’s Half-Year Sales Grow on Global Brands, Profits Slide after EA Pharma One-Off Gain
November 2, 2017
- Mitsubishi Tanabe’s Half-Year Sales Up 4.5%, but Profits Dip on Radicava Promotion Costs
November 2, 2017
- Takeda Logs 3.6% Sales Rise, Double-Digit Profit Jump on Entyvio, Takecab
November 2, 2017
- Astellas Delivers Positive Data in 1st HIF-PH Inhibitor Study in Japan
November 1, 2017
- Aspen Takes Over Arixtra from GSK, Transfer Pact Completed in Japan
November 1, 2017
- Bristol-Myers France’s Barland to Become Japan President
November 1, 2017
- Kyowa Kirin Kicks Off Japan PIII for Regpara Follow-Up Evocalcet
November 1, 2017
- Daiichi Sankyo Shooting for Top Share for Lixiana by Tokyo Olympics: President
November 1, 2017
- Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
November 1, 2017
- Micardis Generic Penetration “Faster than Expected”: Astellas President
November 1, 2017
- Towa to Discontinue Sales of 34 Products due to Bulk Drug Supply Problems, Weak Demand
November 1, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…